News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investors in Ardent Health, Inc. ARDT need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 15, 2027 $25 Call had some of the highest implied volatility of all equity options today. What …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 10:00 a.m. ET CALL PARTICIPANTS Senior Vice President of Investor Relations - Dave Styblo President and Chief Executive Officer - Dave Caspers Chief Financial Officer - Alfred Lumsdaine Full Conference Call Transcript Operator: …
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Ardent Health, Inc. (ARDT) regarding potential corporate wrongdoing by the company and its officers. The firm is encouraging shareholders who purchased Ardent securities before July 18, 2024, and still hold them, to contact them …
Nationally recognized structural heart program first in the country to use the next-generation Supira heart pump in a national clinical trial BRENTWOOD, Tenn. & TULSA, Okla., August 11, 2026--(BUSINESS WIRE)--Oklahoma Heart Institute (OHI), part of Hillcrest HealthCare System and Ardent Health (NYSE: ARDT), is …
RBC Capital Markets has raised its price target for Ardent Health Partners from $12 to $13, while reiterating an Outperform rating on the company's stock. This adjustment reflects an updated valuation by the analysts.
RBC Capital increased its price target for Ardent Health Partners Inc. (NYSE: ARDT) to $13.00 from $12.00, maintaining an Outperform rating, after the company's Q2 2026 adjusted EBITDA exceeded expectations. This performance was attributed to a successful payer contract renegotiation and an accelerated IMPACT …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ardent Health, Inc. (ARDT) securities who bought prior to July 18, 2024, and continue to hold them. The investigation aims to determine if Ardent and its officers/directors engaged in corporate …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ardent Health earnings and guidance reset Ardent Health (ARDT) reported second quarter 2026 results on 4 August, with net income and earnings per share lower than a …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Ardent Health, Inc. (NYSE: ARDT) on behalf of investors who purchased securities before July 18, 2024. The investigation concerns alleged corporate wrongdoing by Ardent and its officers/directors. The firm encourages current stockholders to inquire …
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ardelyx, Inc. ARDX develops and commercializes therapies for gastrointestinal and kidney diseases. The Zacks Consensus Estimate for its current year earnings has been revised 14.3% downward over the last 60 …
Guggenheim increased its price target for Ardent Health Partners Inc. (NYSE: ARDT) to $14 from $13, maintaining a Buy rating after the company's Q2 2026 EBITDA exceeded expectations. The firm noted Ardent Health's strong free cash flow yield and potential for future upside driven …
Ardent Health Partners, LLC discussed its Q2 2026 earnings, focusing on operational optimization and strategic execution to mitigate macroeconomic volatility. The company reaffirmed its Adjusted EBITDA guidance despite weaker Q2 volumes, expecting to offset headwinds with increased savings from its IMPACT program and contracting …
Truist Securities has increased its price target for Ardent Health Partners to $13 from the previous $12, while reiterating a Buy rating on the stock. This adjustment suggests a continued positive outlook from Truist on the company's financial prospects and stock performance.
This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ardent Health Inc (NYSE:ARDT) successfully increased its 2026 Impact Program savings target to at least …
Ardent Health Services reported Q2 2026 adjusted EPS of $0.12, missing the $0.17 forecast, despite revenue reaching $1.62 billion. The company's stock rose 7.81% in after-hours trading due to strong cash flow, tighter cost control, and reaffirmed full-year guidance. Management highlighted cost cuts and …
Ardent Health, Inc. (ARDT) reported Q2 2026 revenue of $1.6 billion, in line with analyst expectations, but experienced a decline in profitability with diluted EPS at $0.12, missing the $0.18 estimate. Despite the profit decline, the company saw stronger cash generation. Insider trading activity …
Ardent Health, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of $0.27, beating estimates by $0.08. The company's revenue reached $1.62 billion, exceeding expectations by $32.57 million despite a 1.40% year-over-year decrease. This presentation provides details on the company's financial performance …
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …
BRENTWOOD, Tenn., August 04, 2026--(BUSINESS WIRE)--Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended June 30, 2026. Second Quarter 2026 Operating and Financial …
Ardent Health, Inc. has provided an update on its equity buyback plan, originally announced on November 18, 2025. Between April 1, 2026, and June 30, 2026, the company repurchased 1.4 million shares for $13 million, representing 0.98% of its equity. Cumulatively, Ardent Health has …
Bronstein, Gewirtz & Grossman, LLC is investigating Ardent Health, Inc. (NYSE: ARDT) for potential corporate wrongdoing. The firm encourages investors who purchased Ardent securities before July 18, 2024, and still hold them, to contact them to assist with the investigation. The firm operates on …
This article provides a risk assessment for Ardent Health Partners Inc (ARDT), noting its current risk assessment score is 3.93, ranking it 51 out of 75 in the Healthcare Providers & Services industry. It details various risk metrics including a beta of 0.00, maximum …
Ardent Health, Inc. (ARDT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results …
This article provides a detailed overview of Ardent Health Partners Inc.'s (ARDT) cash flow statement, including operating, investing, and financing activities. It presents quarterly and annual financial data, highlighting changes in key cash flow metrics like operating cash flow, capital expenditures, and free cash …
This article provides a revenue breakdown for Ardent Health Partners Inc (ARDT), noting the company's market capitalization and P/E TTM ratio. It states that relevant data for revenue by business segment and profit contribution have not yet been disclosed by the company. However, it …
This article presents the quarterly and annual income statements for Ardent Health Partners Inc. (ARDT), detailing key financial metrics such as revenue, operating profit, and net income from FY2022Q1 to FY2026Q1. It allows users to analyze the company's financial performance and operational efficiency. The …
Search by ticker symbol or company name and select a result to open its chart.